Literature DB >> 25986608

Eukaryotic Translation Initiation Factor 4E Is a Feed-Forward Translational Coactivator of Transforming Growth Factor β Early Protransforming Events in Breast Epithelial Cells.

Lindsey Decarlo1, Celine Mestel1, Mary-Helen Barcellos-Hoff2, Robert J Schneider3.   

Abstract

Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed early in breast cancers in association with disease progression and reduced survival. Much remains to be understood regarding the role of eIF4E in human cancer. We determined, using immortalized human breast epithelial cells, that elevated expression of eIF4E translationally activates the transforming growth factor β (TGF-β) pathway, promoting cell invasion, a loss of cell polarity, increased cell survival, and other hallmarks of early neoplasia. Overexpression of eIF4E is shown to facilitate the selective translation of integrin β1 mRNA, which drives the translationally controlled assembly of a TGF-β receptor signaling complex containing α3β1 integrins, β-catenin, TGF-β receptor I, E-cadherin, and phosphorylated Smad2/3. This receptor complex acutely sensitizes nonmalignant breast epithelial cells to activation by typically substimulatory levels of activated TGF-β. TGF-β can promote cellular differentiation or invasion and transformation. As a translational coactivator of TGF-β, eIF4E confers selective mRNA translation, reprogramming nonmalignant cells to an invasive phenotype by reducing the set point for stimulation by activated TGF-β. Overexpression of eIF4E may be a proinvasive facilitator of TGF-β activity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986608      PMCID: PMC4524117          DOI: 10.1128/MCB.00324-15

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  84 in total

Review 1.  Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability.

Authors:  Daniel B Rifkin
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

Review 2.  TGF-beta and epithelial-to-mesenchymal transitions.

Authors:  Jiri Zavadil; Erwin P Böttinger
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

3.  Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein.

Authors:  Ki-Kyung Jung; Xu-Wen Liu; Rosemarie Chirco; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

4.  Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation.

Authors:  Yuri V Svitkin; Barbara Herdy; Mauro Costa-Mattioli; Anne-Claude Gingras; Brian Raught; Nahum Sonenberg
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

5.  Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.

Authors:  Sheng-Ru Shiou; Pran K Datta; Punita Dhawan; Brian K Law; Jonathan M Yingling; Dan A Dixon; R Daniel Beauchamp
Journal:  J Biol Chem       Date:  2006-09-07       Impact factor: 5.157

6.  Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta).

Authors:  Rachel L Clifford; Karl Deacon; Alan J Knox
Journal:  J Biol Chem       Date:  2008-10-23       Impact factor: 5.157

Review 7.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

8.  Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

Authors:  Hong-yu Li; Yan Wang; Charles R Heap; Chi-Hsin R King; Sreenivasa R Mundla; Matthew Voss; David K Clawson; Lei Yan; Robert M Campbell; Bryan D Anderson; Jill R Wagner; Karen Britt; Ku X Lu; William T McMillen; Jonathan M Yingling
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

9.  Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Authors:  Michelle D Martin; Kathy J Carter; Sharon R Jean-Philippe; Mayland Chang; Shahriar Mobashery; Sophie Thiolloy; Conor C Lynch; Lynn M Matrisian; Barbara Fingleton
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis.

Authors:  Kevin K Kim; Ying Wei; Charles Szekeres; Matthias C Kugler; Paul J Wolters; Marla L Hill; James A Frank; Alexis N Brumwell; Sarah E Wheeler; Jordan A Kreidberg; Harold A Chapman
Journal:  J Clin Invest       Date:  2008-12-22       Impact factor: 14.808

View more
  11 in total

1.  Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery.

Authors:  Jiahe Li; Wade Wang; Yanpu He; Yingzhong Li; Emily Z Yan; Ketian Zhang; Darrell J Irvine; Paula T Hammond
Journal:  ACS Nano       Date:  2017-02-14       Impact factor: 15.881

2.  Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Fernanda Musa; Amandine Alard; Gizelka David-West; John P Curtin; Stephanie V Blank; Robert J Schneider
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

Review 3.  Translation initiation factors and their relevance in cancer.

Authors:  Columba de la Parra; Beth A Walters; Phillip Geter; Robert J Schneider
Journal:  Curr Opin Genet Dev       Date:  2017-11-16       Impact factor: 5.578

4.  Adaptations to chronic rapamycin in mice.

Authors:  Sherry G Dodds; Carolina B Livi; Manish Parihar; Hang-Kai Hsu; Adriana D Benavides; Jay Morris; Martin Javors; Randy Strong; Barbara Christy; Paul Hasty; Zelton Dave Sharp
Journal:  Pathobiol Aging Age Relat Dis       Date:  2016-05-27

5.  Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming.

Authors:  Phillip A Geter; Amanda W Ernlund; Sofia Bakogianni; Amandine Alard; Rezina Arju; Shah Giashuddin; Abhilash Gadi; Jacqueline Bromberg; Robert J Schneider
Journal:  Genes Dev       Date:  2017-12-21       Impact factor: 11.361

6.  The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Authors:  Richard E Kast; Nicolas Skuli; Samuel Cos; Georg Karpel-Massler; Yusuke Shiozawa; Ran Goshen; Marc-Eric Halatsch
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-07-11

7.  IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.

Authors:  Rui Liu; Chengyong Tang; Ai Shen; Huating Luo; Xufu Wei; Daofeng Zheng; Chao Sun; Zhongtang Li; Di Zhu; Tingting Li; Zhongjun Wu
Journal:  Oncotarget       Date:  2016-12-20

Review 8.  Role of Eukaryotic Initiation Factors during Cellular Stress and Cancer Progression.

Authors:  Divya Khandige Sharma; Kamiko Bressler; Harshil Patel; Nirujah Balasingam; Nehal Thakor
Journal:  J Nucleic Acids       Date:  2016-12-19

9.  Rapamycin Inhibits the Growth and Collagen Production of Fibroblasts Derived from Human Urethral Scar Tissue.

Authors:  Delai Fu; Jian Yin; Shanlong Huang; Hecheng Li; Zhaolun Li; Tie Chong
Journal:  Biomed Res Int       Date:  2018-04-17       Impact factor: 3.411

10.  Type II alveolar epithelial cell-specific loss of RhoA exacerbates allergic airway inflammation through SLC26A4.

Authors:  Danh C Do; Yan Zhang; Wei Tu; Xinyue Hu; Xiaojun Xiao; Jingsi Chen; Haiping Hao; Zhigang Liu; Jing Li; Shau-Ku Huang; Mei Wan; Peisong Gao
Journal:  JCI Insight       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.